Funding for this research was provided by:
Uniformed Services University of the Health Sciences (HU0001-16-2-0006, HU0001-16-2-0014)
U.S. Department of Defense (W81XWH-16-2-0038)
Received: 6 September 2019
Accepted: 20 February 2020
First Online: 9 March 2020
Ethics approval and consent to participate
: This study was conducted under an IRB exempt protocol (Western IRB approved).
: Not applicable.
: TPC receives research funding from AbbVie. EFP receives research funding from Genentech, Pfizer, AbbVie, and is a co-inventor of the RPPA technology described herein and receives royalties on the related license agreements.